STOCK TITAN

CYTK insider files Rule 144 notice for 15,000-share sale on NASDAQ

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 notice for CYTK reports a proposed sale of 15,000 common shares through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of $824,400 and an approximate sale date of 10/01/2025. The shares were acquired as restricted stock units on 03/06/2021. The filing lists five prior 10b5-1 sales by the same person during Jul–Sep 2025 totalling 25,000 shares and gross proceeds shown for each trade. The filer certifies no undisclosed material adverse information and that the sale complies with Rule 144 and any applicable 10b5-1 plan.

Positive

  • Transparent disclosure of proposed sale details (shares, aggregate value, broker, exchange, and acquisition method)
  • Compliance with Rule 144 and 10b5-1 protocols is documented, including prior sales history and seller certification

Negative

  • Insider selling activity continues: proposed 15,000-share sale plus 25,000 shares sold in Jul–Sep 2025 could increase share supply
  • No plan adoption date or signature details are included in the provided text, limiting context on timing of any 10b5-1 plan

Insights

TL;DR: Insider plans to sell 15,000 shares (~$824k) under Rule 144; recent 10b5-1 activity shows ongoing dispositions.

The filing documents a routine Rule 144 sale of shares originally granted as restricted stock units in 2021. The proposed trade size and disclosed aggregate market value are explicit, and the use of Morgan Stanley Smith Barney indicates brokered execution. The historical 10b5-1 sales (five transactions totalling 25,000 shares across Jul–Sep 2025) suggest a continuing divestiture pattern. This is a disclosure of insider liquidity rather than new corporate events; it informs supply-side dynamics but contains no operational or financial performance data.

TL;DR: Filing is a compliance disclosure showing permitted insider sales; no indication of undisclosed adverse information.

The signer affirms under penalty that they possess no material nonpublic information and cites reliance on Rule 10b5-1 for prior trades where applicable. The disclosure of acquisition date, nature (RSUs), and prior sale history aligns with governance transparency best practices. There is no mention of plan adoption date or additional restrictions in this filing text, so reviewers should rely solely on the provided entries when assessing insider conduct.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 for CYTK report?

It reports a proposed sale of 15,000 common shares on NASDAQ with an aggregate market value of $824,400, to occur approximately on 10/01/2025.

How were the shares acquired that are being sold?

The 15,000 shares were acquired as restricted stock units on 03/06/2021 and payment/nature is listed as N/A in this filing.

Has the seller made recent sales of CYTK shares?

Yes. The filing lists five 10b5-1 sales in Jul–Sep 2025 totaling 25,000 shares with gross proceeds disclosed for each trade.

Through which broker will the proposed sale be executed?

Morgan Stanley Smith Barney LLC (Executive Financial Services, 1 New York Plaza, New York, NY) is listed as the broker.

Does the filing indicate any undisclosed material information?

The filer certifies they do not know any material adverse information that has not been publicly disclosed as part of the Form 144 signature statement.
Cytokinetics Inc

NASDAQ:CYTK

CYTK Rankings

CYTK Latest News

CYTK Latest SEC Filings

CYTK Stock Data

8.29B
119.96M
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO